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Genetic studies of lung disease in Cystic Fibrosis are hampered by the lack of a severity measure
that accounts for chronic disease progression and mortality attrition. Further, combining analyses
across studies requires common phenotypes that are robust to study design and patient
ascertainment.
Using data from the North American Cystic Fibrosis Modifier Consortium (Canadian Consortium
for CF Genetic Studies, Johns Hopkins University CF Twin and Sibling Study, and University of
North Carolina/Case Western Reserve University Gene Modifier Study), the authors calculated
age-specific CF percentile values of FEV1 which were adjusted for CF age-specific mortality data.
The phenotype was computed for 2061 patients representing the Canadian CF population, 1137
extreme phenotype patients in the UNC/Case Western study, and 1323 patients from multiple CF
sib families in the CF Twin and Sibling Study. Despite differences in ascertainment and median
age, our phenotype score was distributed in all three samples in a manner consistent with
ascertainment differences, reflecting the lung disease severity of each individual in the underlying
population. The new phenotype score was highly correlated with the previously recommended
complex phenotype, but the new phenotype is more robust for shorter follow-up and for extreme
ages.
A disease progression and mortality adjusted phenotype reduces the need for stratification or
additional covariates, increasing statistical power and avoiding possible distortions. This approach
will facilitate large scale genetic and environmental epidemiological studies which will provide
targeted therapeutic pathways for the clinical benefit of patients with CF.
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INTRODUCTION
Although cystic fibrosis (CF) is a classic Mendelian disease, there is great variability in the
chronic progressive lung disease which is the principal cause of early mortality. Variation in
lung function, even among patients with the same CFTR mutations, is largely heritable, and
modifier genes are known to influence pulmonary disease severity in CF1-4. Large scale
studies of the role of genetic variation in the severity of CF will potentially lead to novel
therapeutic targets. However, for powerful analysis across the entire genome a phenotypic
measure is required that will accurately represent individual disease severity for all ages, and
across different populations and study designs. The pulmonary disease phenotype is usually
based on forced expiratory volume in one second (FEV1), the most clinically useful measure
of lung function and a known predictor of survival5-7. FEV1 is the volume of air (in liters)
that can be exhaled in one second (after maximal inhalation)8 and is generally reported as a
percent predicted (FEV1pp) based on age, sex, and height9-13. To address the concern that
standard norms may be invalid in CF patients because of stunting and/or delayed puberty,
Kulich et al. designed CF specific percentiles (CF FEV1%ile) to measure lung function
relative to other CF patients of the same age, sex, and height14. Neither FEV1pp nor CF
FEV1%ile account for mortality attrition; patients are compared only to those still alive,
excluding patients from the same birth cohort who have died (usually because of more
severe lung disease).
To derive a measure that accounted for mortality, Schluchter and colleagues developed a
model combining mixed model regression and survival analysis, in which estimates of slope
and intercept for an individual patient’s rate of decline in FEV1pp could be used to predict
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the age at death for that patient5. In an application of this complex model, Schluchter et al.
concluded that estimated FEV1pp at age 20 based on a mixed model approach, wherein
longitudinal FEV1pp values of many patients are analyzed together in a single regression
model, was the most suitable of several phenotypes considered for modifier studies,
equivalent to estimated percentile of predicted age of death15. Although this approach
accounts for survival and has been useful, it has limitations for general application. These
estimates are critically related to the number of measures of lung function, the number of
years over which they were collected, the make-up of the study population, and the changing
patterns of CF survival and lung function in recent decades.
In this paper we describe a novel approach to the development of a robust pulmonary
disease phenotype that allows for both the effects of chronic disease progression and
mortality attrition, and allows the use of less extensive longitudinal data.
METHODS
Patient study samples
We apply our approach to the North American CF Modifier Consortium which consists of
three study groups whose ascertainment schemes differed. The Canadian Consortium for CF
Genetic Studies (CGS) was designed to recruit a representative sample of the Canadian CF
population to identify modifier genes. This sample of 2473 patients was collected from 37
Canadian CF centers between 2000 and 200416. Children under the age of 2 years were
excluded from the study to avoid enrolling newly diagnosed infants in a period of stress and
variable compromise. Longitudinal data from each clinic visit in the three years preceding
entry into the study included FEV1, age, height and weight.
The Johns Hopkins University CF Twin and Sibling Study (TSS) was family-based and
included 1323 patients from 693 families who were recruited from 71 CF centers in the US
and one in Australia4. Individuals with CF who had one or more living siblings with CF
were eligible for inclusion. Patient samples were collected over a period of several years,
most in 2002-2007. Although lifetime clinical information was collected, only the three
years preceding study entry were analyzed herein.
The third sample, from the University of North Carolina at Chapel Hill/Case Western
Reserve University Gene Modifier Study (GMS)2, was an extremes of phenotype design.
The sample included 1137 patients who were homozygous for F508del from 44 US CF
centers who were enrolled between 2000 and 2006. Using data from the US CF Foundation
Patient Registry to define quartiles of FEV1pp using the Knudson equations17, patients were
recruited from one of three groups – severe (lowest quartile for age; 8-25 years); younger
mild (highest quartile for age; 15-28 years); and older mild (highest quartile for ages 29-33
years plus all those at least 34 years, considered mild by virtue of survival). For each patient,
data for the previous five years were collected, but only three years were used in the present
analysis.
Entry criteria for subjects in all three studies included verification of CF diagnostic
information, including elevated sweat tests and CFTR mutation analysis, according to
standard guidelines18.
Phenotype derivation
Age-specific percentile scores—For the population-based CGS sample, mean age and
mean FEV1pp were calculated using data from the three years prior to study enrollment.
Pediatric (Wang et al.13) and adult (Hankinson et al9) reference equations were used as
recommended by the US CF consensus group19 to calculate FEVpp at each visit. Residual
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values from a non-linear regression of mean FEV1pp vs. mean age (see Figure 1) were
converted to rank percentile values to characterize the lung disease severity of each
individual in the surviving population.
Because the TSS and GMS samples were not population based, we adapted the method
described above, to account for variable designs and ascertainment schemes. We calculated
the CF FEV1%ile (Kulich et al.) at each patient visit, and used the mean CF FEV%ile for
each individual to rank him/her among CF survivors.
Computation of cohort survival estimates—The Canadian CF Patient Data Registry
(CPDR) has collected prospective data on all Canadian CF patients since 197320. Patients
included in the CPDR come from a network of audited CF care centers where the criteria for
diagnosis of CF include elevated sweat chloride tests and/or identified CFTR mutations, and
documentation of classic CF symptoms. Virtually all CF patients in Canada are captured in
the CPDR, and the CGS sample is a representative subset. In order to compute birth cohort
survival curves, de-identified birth and death dates, as well as date of last reported visit were
requested on all patients in the 2002 CPDR, following ethics review. For patients born in
1973 or later, survival curves based on two year birth cohorts from the CPDR were created
with a censoring date of 31 December 2002, the approximate midpoint of CGS data
collection. Cohort cumulative survival probabilities on this date were used to create the
survival estimates. For patients born before 1973, survival estimates were created by
dividing the number of CF patients from each birth cohort alive on 31 December 2002 by
the expected number of CF births (Canadian births x 1/2500). Local area regression was
used to compute smoothed estimates of survival across the birth cohorts.
Adjustment of FEV1 percentiles for mortality—An individual’s FEV1 percentile as
computed above gave an estimate of the proportion of surviving patients of the same age, ie
from the same birth cohort, whose lung function was below that individual’s. Multiplying
this number by the estimated survival percentile for that age provided the estimated
proportion of patients from the entire original birth cohort who were surviving with FEV1
values below that of the individual. Adding this value to the proportion of patients from the
original birth cohort who did not survive (1 minus the estimated survival percentile), gave an
estimate of the proportion of patients from the individual’s original birth cohort who had
FEV1 values below that of the individual or who had died, presumably with more severe
lung disease. Transformation of this mortality adjusted cohort percentile to a standard
normal score yielded the Normal Residual Mortality Adjusted (NoRMA) lung disease
phenotype. Application of the survival adjustment to mean CF FEV1%ile and
transformation to a normal score produced the Kulich NoRMA (KNoRMA) phenotype. This
general framework (Table 1) for FEV1 could be applied to any quantitative measure that
varies with age and whose distribution suffers from mortality attrition.
Statistical methods
Local area regression (PROC LOESS in SAS version 9.1) was used to define age-specific
non-linear regression estimates of FEV1pp for NoRMA in the CGS sample, and to create the
final smoothed age-specific survival estimates. Local area regression computes least squares
regression of a dependent variable (here FEVpp) on an independent variables (here age) in
successive small neighbourhoods of the dependent variable and then splices these small
linear regression lines together to produce a curve that is not constrained to any particular
shape. FEV1pp residuals from the LOESS curve were normally distributed at all ages and
showed no age-specific patterns (data not shown), justifying the conversion of the mortality-
adjusted percentile values to normal deviates using SAS PROC PROBIT. SAS PROC
LIFETEST was used to compute birth cohort survival curves from the CPDR data. The three
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years of data that were used to create NoRMA and KNoRMA were also used in a mixed
model analysis (PROC MIXED) to compute two phenotypes proposed by Schluchter: the
predicted value of FEV1pp at age 20 (FEVest20) and the predicted age at death percentile
(AgeDied%ile)5, 15 based on patient specific slope and intercept. The MIXED procedure is a
combination regression model allowing repeated measures for individuals, providing fixed
effect coefficients for the overall effects of intercept and slope as well as random effect
coefficients to calculate subject specific values for intercept and slope. Correlations between
the phenotypes were investigated using PROC CORR.
Estimate of heritability for KNoRMA
Heritability was estimated using the TSS sample, which included twins as well as siblings.
Heritability was calculated from 67 pairs of monozygous twins and 138 pairs of same-sex
dizygous twins and non-twin siblings born within 3 years of each other. The pairwise
correlation coefficient was calculated for each group, with assignment of twins or siblings as
“A” or “B” permuted 106 times. The average of the 106 estimates for monzygous twins and
for same sex dizygous twins or sibs was a robust estimate of the true correlation in each
group, avoiding any bias that may have been introduced by arbitrary or systematic
assignments to A and B status. Heritability was estimated to be twice the difference in the
group mean coefficients4.
RESULTS
Population based CGS patient sample
Representativeness of the CGS sample was assessed by comparison to the 2002 CPDR
Report (Table 2).
Reproducible and reliable FEV1 measurements are typically only obtained in patients six
years and older. Thus, development of the NoRMA phenotype was based on 2061 patients
(1104 males; 957 females), six years of age and older, with 1 to 65 visits with a mean of 9.1
(SD=5.6). The mean age of FEV1 measurements was 20.5 (SD=17.9), ranging from 6.0 to
68.6. FEV1pp ranged from 14.8 to 136.5 with a mean of 73.5 (SD=25.0). Although local
area regression showed a decline in lung function with age, FEV1pp was highly variable at
all ages, and average values at older ages showed no age-related pattern because of mortality
attrition (Figure 1). The age-specific survival estimates used for mortality adjustment are
provided as supplemental information; there was minimal mortality in children (>90%
survival under age 18 years) but survival estimates declined steeply throughout the twenties
and roughly logarithmically after age 30. The dramatic effect of adjusting for mortality
attrition can be seen in Figure 2 which shows the distribution of NoRMA scores across the
age range.
To illustrate the impact of these steps in calculating the severity scores, we compare two
patients, a 10-year-old and a 30-year-old each with FEV1 of 60% of predicted (Table 3).
The 10-year-old had an age-specific percentile score (based on residuals from the LOESS
curve) of 0.10 and the 30-year-old had a score of 0.52. Adjusting for mortality attrition
further improves the score for the 30-year old who is seen to have relatively mild CF lung
disease while the 10-year-old is severely affected.
The two phenotypes based on mixed model analysis 5, 15 were compared to NoRMA in the
CGS sample (1435 unrelated patients). AgeDied%ile was normally distributed with a mean
of 0.50 (SD=0.29). FEVest20 ranged from -31.95% to 135.84% with a mean of 72.56
(SD=20.21). Fifteen patients had FEVest20 less than 15% while four patients had estimates
over 130%. Correlation coefficients for NoRMA, AgeDied%ile and FEVest20 (Table 4)
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were higher in the younger subset, reflecting the limitations of the mixed model estimates at
ages further from age 20, when using only three years of data for each subject.
Generalizing beyond a population-based design (KNoRMA)
Since the GMS and TSS samples were not population based, population percentiles and the
NoRMA phenotype as described above could not be computed. Age-specific CF percentiles
for FEV1 developed by Kulich were used to compute KNoRMA in the three samples (Table
5).
Mean age differed significantly across sites (ANOVA P<0.001). The TSS sample had a
younger mean age than both GCS and GMS (P<0.001). This is consistent with previous
sibling studies, which tend to enroll younger patients than those using a population based
approach 21. Conversely, GMS had an older mean age than the other two groups (P<0.001),
reflecting the fact that mild patients under the age of 15 years were excluded from this study.
There was no significant difference in the sex distributions.
Mean KNoRMA scores of CGS and GMS were not significantly different from each other,
yet both were significantly higher than TSS (P=0.003 and P=0.04, respectively). The
frequency distributions of KNoRMA for each of the three groups are shown in Figure 3. The
distributions in TSS and CGS are very similar, whilst the distribution in GMS was bimodal,
reflecting the ascertainment of patients with extreme lung phenotypes, and the recruitment
of twice as many subjects in the “mild” range of lung disease compared to those in the
“severe” range.
Correlation coefficients between KNoRMA and the mixed model phenotypes in TSS and
GMS are shown in Table 6. Lower correlations in TSS likely reflect the fact that the TSS
sample is younger and further away from the age of 20. Results were unchanged when only
one sibling from each TSS family was used in analysis (data not shown).
Heritability estimate for KNoRMA
The correlation coefficient for KNoRMA in monozygous twins was 0.79 while it was 0.53
for the dizygous twin/sib group. Thus, the heritability estimate was 0.51 (estimated 95%
confidence interval: 0.28, 0.77), similar to that previously reported for the Kulich percentile
alone without mortality adjustment in the TSS cohort4.
DISCUSSION
We used age-adjusted severity disease severity and age-specific survival estimates to define
a novel framework for deriving phenotypes in CF pulmonary disease. One phenotype
(NoRMA) was based on a population based sample, while the second (KNoRMA) used
previously published CF-specific norms for applicability across variable study designs.
These measures of disease severity can be compared across a range of ages, do not require
data from a long period of follow up, and can be used across disparate populations.
Accounting for attrition due to disease-related mortality removes the penalty that occurs
when older patients are compared only against other survivors using simply FEV1pp or CF
FEV1%ile.
The mixed model estimate of FEV1 at age 20 was also designed to adjust for disease
progression and mortality attrition. However, it requires extrapolation of data for patients
older or younger than 20 years of age, meaning that the further from age 20, the less reliable
the estimate. Use of mixed model estimates of slope and intercept to provide estimated death
age percentile is also less robust in the youngest and oldest subjects where flat regression
lines may yield inappropriate estimates beyond the observed measurements. This is
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particularly problematic when combining study samples whose age distributions differ.
These methods were designed for use in studies with extensive longitudinal data. With
limited longitudinal data or cross-sectional data, these disease severity estimates will be
seriously biased for many subjects, while NoRMA and KNoRMA provide valid estimates
based on specific age at time of measurement for each individual. Multiple measurements
can improve precision, but a single measurement is acceptable, so that subjects need not be
deleted from analysis based on arbitrary rules of data availability.
Although the ascertainment schemes of the three CF samples differed drastically, KNoRMA
provided a phenotype that was comparable across the sites. An additional benefit to
KNoRMA (compared to mixed model methods and NoRMA) is that the phenotype estimate
for each subject is independent. With the mixed model and NoRMA, lung function scores
are based on the study sample; adding patients (for example, when working in a consortium)
or removing patients from the sample would affect the results of all other patients. Since
KNoRMA estimates are based on CF population based reference equations, addition or
removal of patients from the analysis has no effect on values for the remaining patients.
There are limitations with this process that must be considered in future studies. The Kulich
percentiles were based on a cohort gathered between 1994 and 200114. It is known that lung
function has improved for CF patients since that time. Therefore, lung function scores
derived using the Kulich reference equations14 were expected to be higher than those
derived by LOESS in the CGS sample. However, this is a known bias, in a known direction,
and we hypothesize that all patients will be affected equally and the analysis of association
with genetic factors should be unbiased. The Kulich scores adjust for lung function
differences between the sexes, which may affect the estimation of potential sex specific
effects in genetic analysis.
Another possible limitation is our use of Canadian-based mortality rates for all samples,
including the US-based study samples recruited by GMS and TSS. However, data from the
US Cystic Fibrosis Foundation’s registry22, from which mortality for birth cohorts from
1985 onwards could be computed, indicated no significant differences in mortality estimates
to age 22 (data not shown). Therefore, we do not believe that our use of Canadian-based
mortality rates introduced a significant bias. Survival estimates were calculated without
accounting for sex. Given historically discordant survival between males and females, future
studies with separate survival estimates may be appropriate. The assumption that all CF
patients who died before a given age had worse lung disease than those who survived to that
age results in a small overestimate of mortality due to lung disease but one that is probably
well within the margin of error of the estimates themselves since lung disease is the primary
cause of death in CF. As national CF data registries around the world become more
extensive, future studies may refine the CF mortality estimates in many ways – by sex, by
country, by precise age, by cause of death – or may develop parametric survival models that
incorporate these factors.
The principles behind this phenotype can be applied to any disease or quantitative phenotype
for which a common measure for the study subjects, compared to the overall patient
population, can be identified and augmented by suitable population mortality rates.
Although our application is to CF, the approach can be used for any trait that is age
dependent and for which cohort survival data are available. For example, in a survey of
Canadians in 2005, 4.4% of those 35 years or older reported that they had been diagnosed by
a health professional with chronic obstructive pulmonary disease (COPD)23. The main
measure of disease severity in COPD is FEV1, which is predictive of other complications
such as cardiovascular disease24, but as lung function progressively worsens in COPD
patients, mortality attrition produces a bias in the comparison of younger versus older
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patients. In cross-sectional studies of FEV1 in COPD, the use of published FEV1 norms and
mortality rates could be used to create a mortality adjusted phenotype which could be used
to find genes that may modify the progression of COPD.
The use of a disease progression and a mortality adjusted phenotype reduces the need for
stratification or additional covariates in large scale genetic and epidemiological studies,
increasing the power of analysis and avoiding possible distortions. This advantage will be
critical25 for the identification of true genetic influences that will translate to targeted
therapies for individuals with high risk genotypes. In future, the inclusion of other factors
related to disease progression or mortality, such as sex or early events such as poor growth
or age of first serious infection, could be incorporated into the severity score, to provide a
more refined measure to investigate prognosis and treatment.
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Montreal, QC, J.E. Marcotte M.D., V. Fauvel, N Bureau, R. Dicaire; Hopital de Chicoutimi,
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Jeanneret M.D. ,M. van Spall M.D., R. Levesque; Montreal Children’s Hospital, Montreal,
QC, L. Lands M.D., M. Gaul.
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(M.F. Guill); Illinois: Northwestern University Feinberg School of Medicine, Chicago (S.A.
McColley); Children’s Memorial Hospital, Chicago (S.A. McColley, E.M. Potter); Indiana:
Riley Hospital for Children, Indianapolis (M.S. Howenstine); Iowa: University of Iowa,
Iowa City (R.C. Ahrens, M. Teresi); Maryland: Johns Hopkins University School of
Medicine, Baltimore (P.L. Zeitlin, L. Brass); Massachusetts: Children’s Hospital, Boston (H.
Levy, I. Huntington); Michigan: Michigan State University Cystic Fibrosis Center, East
Lansing (R.E. Honicky); Michigan: Children’s Hospital of Michigan–Wayne State, Detroit
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Jackson (F.E. Ruiz, K.G. Adcock); Missouri: Saint Louis University, St Louis (B.E. Noyes,
V.L. Kociela); Missouri: University of Missouri, Columbia (P. Konig); Missouri:
Washington University School of Medicine, St Louis (T. Ferkol Jr, M. Boyle); Nebraska:
University of Nebraska Medical Center, Omaha (J.L. Colombo); New Hampshire:
Dartmouth Hitchcock Medical Center, Lebanon (H.W. Parker); New Jersey: Atlantic Health/
Morristown Memorial Hospital, Morristown (S.B. Fiel, P. Lomas).; New Jersey: Monmouth
Medical Center, Long Branch (R.L. Zanni); New Mexico: University of New Mexico,
Albuquerque (J. Taylor-Cousar); New York: Columbia University, New York (E.A.
DiMango); New York: Schneider Children’s Hospital, New Hyde Park (J.K. DeCelie-
Germana); New York: St. Vincent’s Hospital, New York (P.A. Walker, M.N. Berdella, E.
Langfelder-Schwind); New York: The Women and Children’s Hospital of Buffalo, Buffalo
(D. Borowitz); New York: University of Rochester, Rochester (C.L. Ren, A.K. Rovitelli);
New York: Upstate Medical University, SUNY, Syracuse (R.D. Anbar, D.M. Lindner);
North Carolina: Duke University, Durham (J. Taylor-Cousar, J.A. Voynow, K.J. Auten);
North Carolina: University of North Carolina at Chapel Hill (M.R. Knowles, M.W. Leigh);
North Carolina: Wake Forest University Baptist Medical Center, Winston-Salem (M.S.
Schechter); Ohio: Akron Children’s Hospital, Akron (G.J. Omlor, D.A. Ouellette); Ohio:
Cincinnati Children’s Hospital, Cincinnati (C.L. Karp); Ohio: Nationwide Children’s
Hospital, Columbus (K.S. McCoy); Ohio: Rainbow Babies and Children’s Hospital, CWRU,
Cleveland (M.W. Konstan); Ohio: Toledo Children’s Hospital, Toledo (P.A. Vauthy, M.L.
Vauthy); Ohio: University of Cincinnati Medical Center, Cincinnati (P.M. Joseph);
Pennsylvania: Children’s Hospital of Philadelphia–University of Pennsylvania, Philadelphia
(T.F. Scanlin, R. Rubenstein, C. Murray, M. Skotleski); Pennsylvania: Drexel University
College of Medicine, Philadelphia (S.B. Fiel, W.P. Sexauer, A. Ko, J. Hillman);
Pennsylvania: Penn State Children’s Hospital and Penn State University College of
Medicine, Hershey (N.J. Thomas, J.C. Hess); Pennsylvania: University of Pittsburgh,
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Pittsburgh (D.M. Orenstein); Rhode Island: Rhode Island Hospital, Providence (M.S.
Schechter); South Carolina: Medical University of South Carolina, Charleston (P.A. Flume);
Tennessee: Vanderbilt University Medical Center, Nashville (P.E. Moore, B. Slovis);
Tennessee: University of Tennessee Health Science Center, Memphis (R. Schoumacher, B.
Culbreath); Texas: Texas Children’s Hospital–Baylor, Houston (P.W. Hiatt); Texas:
University of Texas Health Science Center, Tyler (R. Amaro, L. Macleod); Texas: Wilford
Hall Medical Center, San Antonio (K.N. Olivier); Utah: University of Utah Pulmonary
Division, Salt Lake City (T.G. Liou); Virginia: University of Virginia Medical Center,
Charlottesville (D.K. Froh); Washington: Seattle Children’s Hospital/University of
Washington, Seattle (R.L. Gibson, S. McNamara, K. Worrell); University of Washington
School of Medicine, Seattle (S.M. Moskowitz); West Virginia: West Virginia University,
Morgantown (K.S. Moffett, L.S. Baer).; Wisconsin: Children’s Hospital of Wisconsin,
Milwaukee (T. Miller); Wisconsin: Medical College of Wisconsin, Milwaukee (J. Biller);
Wisconsin: University of Wisconsin Adult Cystic Fibrosis Center, Madison (G.A. do Pico,
L.M. Makholm); University of Wisconsin, CF-Pediatric Pulmonary Center, Madison (M.J.
Rock, S.R. Osmond).
The Johns Hopkins University CF Twin and Sibling Study
AK: Providence Medical Center, Anchorage CF Clinic, Anchorage (Dion Roberts, MD,
Vicki Roberts); AL: University of Alabama at Birmingham, Children’s Hospital,
Birmingham (Hector Gutierrez, MD, Valerie Eubanks Tarn); AR: Sparks Regional Medical
Center , Fort Smith (Louay Nassri, MD); AZ: Phoenix Children’s Hospital, CF Center,
Phoenix (Gerald Gong, MD, Natalia Argel); AZ: Tuscon Cystic Fibrosis Center , Tucson
(Wayne Morgan, MD); CA: Sutter Medical Center , Sacramento (Bradley Chipps, MD,
Kasey Pearson); CA: Children’s Hospital - Oakland, Pediatric Pulmonary Center, Oakland
(Karen Hardy, MD); CA: Children’s Hospital of Orange County , Orange (David Hicks,
MD); CA: Pediatric Diagnostic Center , Ventura (Chris Landon, MD); CA: Kaiser
Permanente Southern California, Kaiser-Permanente, Panorama City (Allan Lieberthal, MD,
Joan Franco); CA: Stanford University Medical Center, Pediatric Pulmonary Medicine, Palo
Alto (Richard Moss, MD, Coleen Dunn); CA: University of California at San Francisco,
Cystic Fibrosis Center, San Francisco (Dennis Nielson, MD); CA: Children’s Hospital of
Los Angeles, University of Southern California, Los Angeles (Arnold Platzker, MD); CA:
Kaiser Permanente Medical Center, Department of Pediatrics, Oakland (Gregory Shay, MD,
Mary Seastrand); CA: Naval Medical Center - San Diego, Attn: Department of Pediatric
Pulmonary, San Diego (Henry Wojtczak, MD); CO: University of Colorado Health Sciences
Center, Children’s Hospital of Denver, Denver (Frank Accurso, MD, Shelley Mann); CT:
Yale University SOM, Pediatric Respiratory Medicine, New Haven (Marie Egan, MD, Jane
Young); CT: Connecticut Children’s Medical Center, Central Connecticut Cystic Fibrosis
Center, Hartford (Craig Lapin, MD, Ginnie Drapeau); FL: University of Florida, CF and
Pediatric Pulmonary Disease Center, Gainesville (Veena Antony, MD); FL: St. Mary’s
Medical Center, CF Center, West Palm Beach (Maurice Cruz, MD, Lisa Middleton); FL:
Miami Children’s Hospital , Miami (Maria Franco, MD, Hilda Santrock); FL: University of
South Florida, All Children’s Hospital, CF Center, St. Petersburg (Magdalen Gondor, MD,
Jennifer Flanery); FL: Joe DiMaggio Children’s Hospital, Pulmonary Center, Hollywood
(Morton Schwartzman, MD); GA: Medical College of GA , Augusta (Margaret Guill, MD,
Kathy Dyer); GA: Emory University School of Medicine, Department of Pediatrics, Atlanta
(Michael Schechter, MD); GA: Georgia Pediatric Pulmonology Assoc., PC, Children’s
Health Care of Atlanta at Scottish Rite, Atlanta (Peter Scott, MD); IA: University of Iowa
Hospitals & Clinics , Iowa City (Richard Ahrens, MD, Mary Teresi and Jean Frauenholtz);
IA: University of Iowa Hospitals & Clinics, Adult CF Program, Iowa City (Douglas
Hornick, MD); ID: St. Luke’s CF Clinic, Children’s Special Health Program, Boise (Henry
Thompson, MD, Mary Nelsen); IL: Lutheran General Children’s Hospital, Nesset Health
Taylor et al. Page 10













Center, Park Ridge (Gabriel Aljadeff, MD); IL: Children’s Asthma Respiratory&Exercise
Specialists , Glenview (Steven Boas, MD); IL: University of Chicago Children’s Hospital,
CF Center, Chicago (Lucille Lester, MD); IL: Children’s Memorial Hospital &
Northwestern University , Chicago (Susanna McColley, MD, Eileen Potter and Cathy
Powers); IL: University of Chicago Hospitals , Chicago (Edward Naureckas, MD); IN: Riley
Hospital for Children, Indiana University SOM, Indianapolis (Michelle Howenstine, MD,
Mary Blagburn); IN: Lutheran Hospital, Cystic Fibrosis and Pediatric Pulmonary Clinic,
Fort Wayne (Pushpom James, MD); KS: Via Christi, St. Francis Campus , Wichita (Daniel
Doornbos, MD); KS: University of Kansas Medical Center, CF Center, Kansas City (Gayln
Perry, MD); KS: Via-Christi- St. Francis Campus, CF Care and Teaching Center, Wichita
(Maria Riva, MD, Janet Messamore); KY: University of Kentucky, Department of Pediatric
Pulmonology, Lexington (Jamshed Kanga, MD); MA: University of Massachusetts
Memorial Health Care , Worcester (Brian O’Sullivan, MD, Dawn Baker); MA: Children’s
Hospital of Boston, Pulmonary Division, Boston (Terry Spencer, MD, Magen Lorenzi and
others); MA: New England Medical Center, CF Center, Boston (William F. Yee, MD,
Corrie DeDomenico); MD: Johns Hopkins Hospital , Baltimore (Michael Boyle, MD); MD:
National Naval Medical Center , Bethesda (Andrew Lipton, MD); MD: Johns Hopkins
Hospital, CF Center, Baltimore (Pamela Zeitlin, MD); ME: Eastern Maine Medical Center,
Pennobscott Pediatrics, Bangor (Thomas Lever, MD, Rebecca Welsh); MI: University of
Michigan Medical Center , Ann Arbor (Samya Nasr, MD, Dawn Kruse); MN: University of
Minnesota, CF Center, Minneapolis (Jordan Dunitz, MD, Brooke Noren); MN: Children’s
Hospitals and Clinics of Minneapolis , Minneapolis (John McNamara, MD, Mahrya
Johnson); MN: University of Minnesota , Minneapolis (Warren Regelmann, MD, Brooke
Noren); MO: Children’s Mercy Hospital, University of Missouri at Kansas City, Kansas
City (Philip Black, MD, Jaylene Wiegel); MO: St. Louis Children’s Hospital, Washington
University School of Medicine, St. Louis (Thomas Ferkol, MD, Mary Boyle); MS:
University of Mississippi Medical Center, Pediatric Pulmonary Division Adult CF Center,
Jackson (Suzanne Miller, MD); MS: Memphis Lung Physicians , Southhaven (William
Richards, MD); MT: Great Falls Clinic , Great Falls (Jerald Eichner, MD); NC: Asthma &
Allergy Specialists, PA , Charlotte (Hugh Black, MD 2); NC: UNC at Chapel Hill, CF
Pulmonary Research and Treatment Center, Chapel Hill (Michael Knowles, MD); NC: UNC
at Chapel Hill, University of North Carolina, Chapel Hill (George Retsch-Bogart, MD); ND:
St. Alexius Heart & Lung CF Clinic , Bismarck (Carla Zacher, MD, Deb McPherson); NE:
University of Nebraska Medical Center , Omaha (John L. Colombo, MD, Dee Acquazino);
NE: University of Nebraska Medical Center , Omaha (Peter Murphy, MD); NH: Dartmouth-
Hitchcock Medical Center , Lebanon (H. Worth Parker, MD); NJ: Morristown Memorial
Hospital , Morristown (Stanley Fiel, MD, Paula Lomas); NJ: University of Medicine &
Dentistry of NJ, Cystic Fibrosis Center, Newark (Nelson Turcios, MD); NJ: Monmouth
Medical Center , Long Branch (Robert Zanni, MD, Bridget Marra); NM: University of New
Mexico, SOM, Pediatrics/Pulmonary, Albuquerque (Lea Davies, MD); NY: SUNY Upstate
Medical University , Syracuse (Ran Anbar, MD, Donna Lindner); NY: Saint Vincents
Hospital & Medical Center, CF Center, New York (Maria Berdella, MD, Elinor Langfelder-
Schwind); NY: Women & Children’s Hospital of Buffalo, Cystic Fibrosis Center at SUNY,
Buffalo (Drucy Borowitz, MD, Jeanne Smith); NY: Women & Children’s Hospital of
Buffalo, Cystic Fibrosis Center at SUNY, Buffalo (Joe Cronin, MD); NY: Schneider
Children’s Hospital, North Shore Long Island Jewish Health system, New Hyde Park (Joan
DeCelie-Germana, MD, Sue Galvin); NY: New York Medical College/Westchester Medical
Center, Pediatric Pulmonology, Valhalla (Allen Dozor, MD, Ingrid Gherson); NY: Long
Island College Hospital, Pediatric CF Center, Brooklyn (Robert Giusti, MD); NY:
University of Rochester Medical Center, Strong Memorial Hospital, Division of pediatric
Pulmonology & Allergy, Rochester (Clement Ren, MD, Marissa Dixon); NY: Albany
Medical College, Adult CF Program, Albany (Jonathan Rosen, MD, Kathy Mokhiber); NY:
Long Island College Hospital, Adult CF Center, Brooklyn (Peter Smith, MD); OH:
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Cincinatti Children’s Hospital and Medical Center, Division of Pulmonary Medicine, C5,
Cincinnati (James Acton, MD, Lorrie Duan); OH: Rainbow Babies and Children’s Hospital,
Pediatric Pulmonary Division, Cleveland (Michael Konstan, MD, Colette Bucur); OH:
Children’s Hospital Medical Center of Akron, Lewis H Walker CF Center, Akron (Nathan
Kraynack, MD, Debbie Oulette); OH: Toledo Children’s Hospital, Adult CF Program,
Toledo (Jeff Lewis, MD); OH: Columbus Children’s Hospital, Pulmonary Department,
Columbus (Karen McCoy, MD, Debbi Johnson); OH: Children’s Hospital Medical Center of
Akron, Adult Program, Akron (Titus Sheers, MD); OH: Toledo Children’s Hospital , Toledo
(Pierre Vauthy, MD, Mary Vauthy); OK: Oklahoma Cystic Fibrosis Center, Tulsa, Pediatric
Clinic, Tulsa (John Kramer, MD); OK: Childrens Hospital of Oklahoma, Univ. of Oklahoma
Health Sciences Ctr., Oklahoma City (James Royall, MD); OR: Kaiser Permanente,
Northwest Region, Portland (Richard Cohen, MD , Megan Buckholtz); PA: University of
Pennsylvania , Philadelphia (Douglas Holsclaw, MD, Marianne Ferrin); PA: Children’s
Hospital of Pittsburgh, University of Pittsburgh, Pittsburgh (David Orenstein, MD, Sandra
Hurban); PA: Children’s Hospital of Philadelphia, CHOP, Philadelphia (Ron Rubenstein,
MD); PA: St. Christopher’s Hospital for Children, Cystic Fibrosis Center, Philadelphia
(Laurie Varlotta, MD); RI: Brown University Medical School Rhode Island Hospital, CF
Center, Providence (Mary Passero, MD); SC: Pediatric Pulmonary Associates. , Columbia
(Daniel Brown, MD); SC: Medical University of South Carolina, Division of Pulmonary
Care and Critical Care, Charleston (Patrick Flume, MD, Sue Gray); TN: University of
Tennessee , Memphis (Richard Boswell, MD); TN: TC Thompson Children’s Hospital ,
Chattanooga (Joel Ledbetter, MD); TN: Vanderbilt University Medical Center, Vanderbilt
Children’s Hospital, Nashville (Elizabeth Perkett, MD, Cathy Tuzeneu); TN: University of
Tennessee, LeBonheur Children’s Medical Center, Memphis (Dennis/Robert Stokes, MD ,
Barbara Culbreath); TX: University of Texas at Tyler Health Center, Pediatric Pulmonology,
Tyler (Rodolfo Amaro, MD, Janice Hoeft); TX: Cook Children’s Medical Center , Fort
Worth (James Cunningham, MD, Sara Scott); TX: Texas Children’s Hospital, Baylor CF
Care Center, Houston (Peter Hiatt, MD, Charlene Hallmark); TX: Baylor College of
Medicine, The Methodist Hospital, Houston (Marcia Katz, MD); TX: Methodist Children’s
Hospital , San Antonio (Martha Morse, MD); TX: Children’s Medical Center of Dallas, CF
Center, Dallas (Claude Prestidge, MD, Andrew Hebert); UT: University of Utah Health
Sciences Center, Intermountain Pediatric CF Center, Salt Lake City (Barbara Chatfield, MD,
Jane Vroom); VA: University of Virginia Health System , Charlottesville (Deborah Froh,
MD, Lauren Ahrens); VA: Naval Medical Center - Portsmouth, Department of Pediatrics,
Portsmouth (Reese Lee, MD); VT: Fletcher Allen Health Care, CF Center, Burlington
(Thomas Lahiri, MD, Jackie Swartz); WA: Childrens Hospital & Regional Medical Center,
Division of Pulmonary Medicine, Mailstop CH-68, Seattle (Ronald Gibson, MD, Alan
Genatassio); WI: Children’s Hospital of Wisconsin, Froedert and Medical College of
Wisconsin, Milwaukee (Julie Biller, MD); WI: Children’s Hospital of Wisconsin, Children’s
Hospital and Health System, Millwaukee (William Gershan, MD, Tami Miller); WI: St.
Vincent Hospital - Genetics , Green Bay (Peter Holzwarth, MD, Sumedha Ghate); WI:
University of Wisconsin Hospital , Madison (Michael Rock, MD, Linda Makholm); WI:
Marshfield Clinic, 1000 North Oak St, Marshfield (Bradley Sullivan, MD, Christina
Zaleski); WV: West Virginia University, Mountain State Cystic Fibrosis Center,
Morgantown (Kathryn Moffett, MD, Linda Baer); Australia: Royal Children’s Hospital ,
Brisbane, Queensland (Claire Wainwright, Joyce Cheney and Mary Jackson); Australia: The
Prince Charles Hospital , Brisbane, Queensland (Scott Bell, MD, Michelle Wood); Scotland:
Royal Hospital for Sick Children , Scotland (Ann Devenny, MD)
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Cross-sectional plot of mean FEV1pp by mean age for 2061 CGS patients. Non-linear
smoothed regression is plotted with 2 standard errors of the mean. Mean is based on the
mean value of three years of data preceding study enrollment.
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Cross-sectional plot of NoRMA score by mean age for 2061 CGS patients.
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Frequency distributions of KNoRMA in the three study samples: 1137 GMS patients, 1323
TSS patients, and 2061 CGS patients.
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Table 1
Generic Framework on Which the FEV1-Based Phenotype was Created.
1 Calculate age-specific FEV1 percentile score (X) for each patient, using either residuals from a sample based regression (as was
done for NoRMA) or published disease specific reference equations (as in KNoRMA).
2 Estimate cohort survival percentile for each age in 0.01 year intervals (S).
3 Calculate age-specific mortality percentile (1-S), to adjust FEV1 percentile.
4 Calculate age-specific, survival adjusted FEV1 percentile: X*S+(1-S).
5 Transform the age-specific survival adjusted FEV1 percentile to a normal score for the final phenotype.
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Table 2
Comparison of CGS Sample to the Overall Canadian CF Population.
CGS Sample (subset of CPDR) CPDR
Number of Patients 2473 3500
Age (Mean) 19.6a 18.8
Sex, %male 53.4% 52.4%
FEV1pp (Mean) 72.2 74.1




Patients under 2 years of age were excluded from the CGS sample producing a slightly higher mean.
b
Although not included in the CPDR report, the prevalence of 88% for PI is consistent with previous reports23.
c
F508del is the most common CF-causing mutation.
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Table 3
Effect of NoRMA Calculations in Two Patients (10 Year and 30 Years of Age) – With the Same FEV1pp
Values.
Younger Patient Older Patient
Age 10 years 30 years
FEV1pp 60 60
Age-specific FEV1pp Percentile 0.10 0.52
Estimated Survival Percentile 0.97 0.49
Survival Adjusted FEV1 Percentile 0.12 0.76
NoRMA -1.14 0.71
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Table 4
Correlation Coefficients for Three Measures of Lung Disease Severity in 1435 Unrelated CGS Patients (Upper
Section) and in a Subset of 917 Unrelated CGS Patients Aged 10-30 Years (Lower Section).
CGS Patients Aged 6-50 Years (n = 1435) NoRMA AgeDied%ile FEVest20
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Table 5
Comparison of Patient Characteristics in the CGS, GMS, and TSS Samples.
CGS GMS TSS
Number of Patients 2061 1137 1323
Age, mean (SD) 20.5 (11.4) 23.1 (10.2) 16.3 (9.1)
Sex, %male 53 53 52
%F508del/F508del 53.0 100 55.5
Number of useable visits per patient, mean (SD) 9.1 (5.6) 15.2 (11.9) 14.4 (9.8)
KNoRMA, mean (SD) 0.56 (0.85) 0.54 (0.96) 0.47 (0.79)
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Table 6
Correlation Coefficients Between Three Measures of Lung Disease Severity in 1323 TSS Patients (Upper
Section) and 1137 GMS Patients (Lower Section).
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